Stocks · News reference

Rothschild & Co Initiates Coverage On ResMed with Neutral Rating, Announces Price Target of $230

Aug 19, 2026, 2:47 PMBenzinga Newsdesk

Rothschild & Co analyst Jackson Philips initiates coverage on ResMed (NYSE:RMD) with a Neutral rating and announces Price Target of $230.

Read original source More stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: benzinga
Observed: Aug 19, 2026, 2:47 PM
Checked: Aug 19, 2026, 2:47 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaAug 19, 2026, 5:45 PMBenzinga Newsdesk
ResMed shares are trading higher after Rothschild & Co. initiated coverage on the stock with a Neutral rating and announced a $230 price target.
Read original at benzinga
RMD
BenzingaAug 7, 2026, 8:11 PMBenzinga Newsdesk
RBC Capital Maintains Sector Perform on ResMed, Raises Price Target to $244
RBC Capital analyst Craig Wong-Pan maintains ResMed (NYSE:RMD) with a Sector Perform and raises the price target from $234 to $244.
Read original at benzinga
RMD
BenzingaAug 7, 2026, 6:18 PMBenzinga Newsdesk
ResMed shares are trading lower after multiple analyst firms lowered their respective price targets on the stock.
Read original at benzinga
RMD